Abstract-Endothelial progenitor cells (EPCs) contribute to endothelial regeneration. Angiotensin II (Ang II) through Ang II type 1 receptor (AT 1 -R) activation plays an important role in vascular damage. The effect of Ang II on EPCs and the involved molecular mechanisms are incompletely understood. Stimulation with Ang II decreased the number of cultured human early outgrowth EPCs, which express both AT 1 -R and Ang II type 2 receptor, mediated through AT 1 -R activation and induction of oxidative stress. Ang II redox-dependently induced EPC apoptosis through increased apoptosis signal-regulating kinase 1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase phosphorylation; decreased Bcl-2 and increased Bax expression; and activation of caspase 3 but had no effect on the low cell proliferation. In addition, Ang II impaired colony-forming and migratory capacities of early outgrowth EPCs. Ang II infusion diminished numbers and functional capacities of EPCs in wild-type (WT) but not AT 1 a-R knockout mice (AT 1 a
A ctivation of the angiotensin II (Ang II) type 1 (AT 1 ) receptor by Ang II leads to several molecular and cellular events that are involved in atherogenesis, and, thus, AT 1 receptor activation is considered to play an important role in endothelial damage and atherosclerosis development and progression. 1, 2 Animal models and clinical trials with blockers of the renin-angiotensin system have confirmed this notion. [3] [4] [5] [6] [7] [8] Diminished endothelial regeneration is considered to play an important role in the pathogenesis of atherosclerosis. 2 Endothelial regeneration is not only accomplished by resident endothelial cells but also by endothelial progenitor cells (EPCs). EPCs are premature circulating cells that are mainly derived from the bone marrow (BM) and that are involved in postnatal vasculogenesis and reendothelialization after endothelial damage and in atherosclerosis-prone vascular areas. 9 -12 EPCs are defined according to surface markers and properties. One recent classification distinguishes between early outgrowth EPCs, which display paracrine actions, and late outgrowth EPCs, which are characterized by high proliferative potential, by differentiating between cellular functional capacities, time of appearance during cell culture, and the cell culture protocol used. 13 Endogenous mobilization or systemic application of EPCs leads to enhancement of reendothelialization, improvement of angiogenesis and endothelial function, decreased neointima formation, and reduced development of atherosclerosis. 11,14 -20 Cardiovascular risk factors and atherosclerosis are characterized by dysfunctional and numerically reduced EPCs, and decreased numbers and impaired function of circulating EPCs are associated with endothelial dysfunction and poor cardiovascular outcomes in patients with coronary artery disease. 17, [21] [22] [23] In this study, we investigated the impact of Ang II on number and function of EPCs, the mechanisms involved, and the relevance of this interplay for vascular damage and regeneration.
Methods
The Methods section of this article can be found in the online Data Supplement (please see http://hyper.ahajournals.org).
Results

Characterization of Human Early Outgrowth EPCs
Human mononuclear cells (MNCs) were isolated from peripheral blood and cultured on fibronectin in supplemented endothelial basal medium. Fibronectin-adherent cells double positive for Dil-labeled, acetylated low-density lipoprotein (Dil-acLDL), and lectin staining were considered early outgrowth EPCs ( Figure S1A of the online Data Supplement; please see http://hyper.ahajournals.org). After 7 days of culture, 71Ϯ7% of all 4Ј,6-diamidino-2-phenylindole-positive cells were Dil-acLDL/lectin double positive (nϭ6). Quantitative immunocytochemical analysis revealed that DilacLDL/lectin double-positive cells expressed the endothelial markers vascular endothelial growth factor receptor 2 (100Ϯ0%), phospho-endothelial NO synthase (100Ϯ0%), and CD31 (84Ϯ8%); the angiotensin receptors AT 1 (76Ϯ8%) and Ang II type 2 (74Ϯ2%); and to some degree the stem cell marker CD34 (18Ϯ1%; nϭ3 to 4; Figure S1B ).
Effect of Ang II on Early Outgrowth EPC Number and Function In Vitro
MNCs were cultured for 7 days as described above in the presence of Ang II or vehicle. Treatment with 10 Ϫ10 to 10 Ϫ6 mol/L of Ang II led to a significant reduction of early outgrowth EPC numbers compared with control, with a decrease of both 4Ј,6-diamidino-2-phenylindole-positive and Dil-acLDL/lectin double-positive cells ( Figure 1 A and B), and without significant differences in the ratios of doublepositive to 4Ј,6-diamidino-2-phenylindole-positive cells (data not shown). Coincubation experiments with Ang II, AT 1 , and Ang II type 2 receptor antagonists revealed that AT 1 receptor activation but not Ang II type 2 receptor activation was essential for the Ang II-mediated effect on early outgrowth EPC numbers ( Figure 1C ). In addition, Ang II decreased functional capacities of early outgrowth EPCs. As shown in Figure 1D and 1E, incubation with Ang II reduced the number of colony forming units and migratory capacity. Both effects were inhibited by AT 1 receptor blocker cotreatment.
Effect of Ang II on Early Outgrowth EPC Proliferation and Apoptosis In Vitro
The rate of proliferating cells, as determined by 5-bromodeoxyuridine incorporation, was very low in early outgrowth EPCs, and incubation with Ang II had no further effect on cell proliferation (5-bromodeoxyuridine-positive cells: control, 0.17Ϯ0.07%; Ang II, 0.11Ϯ0.05%), as shown in Figures 2A and S2 . This was confirmed by immunocytochemistry for the proliferation marker Ki-67 in Dil-acLDL/ lectin double-positive early outgrowth EPCs, which showed that only 1Ϯ0.5% of these cells were Ki-67 positive after 7 days of culture ( Figure 2B ). In contrast, control experiments with human coronary artery endothelial cells and human umbilical vein endothelial cells revealed proliferation rates of 71% and 64%, respectively ( Figure S2 ). Figure 2C demonstrates that Ang II significantly increased the rate of apoptosis in early outgrowth EPCs, which was inhibited by AT 1 receptor blocker cotreatment. This was confirmed by immunocytochemistry for the apoptosis marker cleaved (active) caspase 3 in Dil-acLDL/lectin doublepositive early outgrowth EPCs ( Figure 2D and 2E ).
To identify a potential signaling pathway underlying the Ang II-induced increase in early outgrowth EPC apoptosis, the apoptosis signal-regulating kinase 1 (ASK-1)-dependent proapoptotic signaling pathway was investigated. Western blot analyses revealed that Ang II increased phosphorylation of ASK-1, phosphorylation of c-Jun N-terminal kinase, and phosphorylation of p38 mitogen-activated protein kinase; decreased the expression of antiapoptotic Bcl-2; and increased the expression proapoptotic Bax, which subsequently initiates activation of caspases, such as caspase 3, and induction of apoptosis (Figures 2F to 2I and S3).
Effect of Ang II on Oxidative Stress in Early Outgrowth EPCs In Vitro
As shown in Figure 3A and 3B, Ang II significantly increased intracellular reactive oxygen species production in early outgrowth EPCs, which was inhibited by an AT 1 receptor blocker and the antioxidant polyethylene glycol-conjugated superoxide dismutase. Coincubation with the antioxidants polyethylene glycol-conjugated superoxide dismutase or tiron completely abolished the Ang II-mediated reduction of early outgrowth EPC numbers, indicating that oxidative stress is involved in this action of Ang II ( Figure 3C ). As demonstrated in Figure 3D to 3G, both Ang II-induced activation of ASK-1, as determined by ASK-1 phosphorylation, as well as Ang II-mediated induction of apoptosis, as determined by active caspase 3 immunocytochemistry, were blocked by coincubation with the antioxidant polyethylene glycol-conjugated superoxide dismutase, indicating that Ang II-induced oxidative stress mediates proapoptotic ASK-1 signaling and, ultimately, apoptosis in early outgrowth EPCs.
Effect of Ang II on EPC Number and Function In Vivo
Wild-type (WT) and AT 1 Ϫ/Ϫ mice were treated with Ang II or vehicle via osmotic minipumps, and numbers and functional capacities of peripheral blood and spleen-derived EPCs were assessed. Ang II infusion led to a significant blood pressure increase in WT but not AT 1 Ϫ/Ϫ mice (systolic blood pressure: WT control, 122Ϯ2 mm Hg; WT Ang II, 168Ϯ2 mm Hg, PϽ0.05 versus WT control; AT 1 Ϫ/Ϫ control, 81Ϯ7 mm Hg; AT 1 Ϫ/Ϫ Ang II, 93Ϯ8 mm Hg, P value not significant versus AT 1 Ϫ/Ϫ control). As shown in Figure 4 , treatment of WT mice with Ang II led to significantly decreased numbers of circulating Sca-1/Flk-1-positive cells in peripheral blood and significantly reduced the number of Dil-acLDL/lectin double-positive cells, colony forming unit formation, and migratory capacity of spleen-derived early outgrowth EPCs. Vehicle-treated AT 1 Ϫ/Ϫ mice showed significantly higher numbers of peripheral blood Sca-1/Flk-1-positive cells and spleen-derived Dil-acLDL/lectin double-positive early outgrowth EPCs than vehicle-treated WT mice, whereas no significant difference was found with regard to colonyforming and migratory capacities (Figure 4) . Importantly, the in vivo effects of Ang II on EPC numbers and function observed in WT mice were completely abolished in AT 1 Ϫ/Ϫ mice, as depicted in Figure 4 .
Effect of Ang II on Neointima Formation and Reendothelialization In Vivo
To assess functional effects of Ang II-mediated reduction of number and function of EPCs in vivo, mice were treated with Ang II or vehicle via osmotic minipumps, and focal carotid artery injury was induced. As shown in Figure 5A and 5B, treatment of WT mice with Ang II significantly enhanced neointima formation after carotid injury. This Ang II effect was abolished in Ang II-treated AT 1 Ϫ/Ϫ mice. Consistently, treatment of WT mice with Ang II significantly decreased reendothelialization after electric carotid endothelial injury, as visualized by Evans blue stainings ( Figure 5C ).
To further assess the functional in vivo relevance of Ang II stimulation and AT 1 receptor expression on EPCs for reendothelialization capacities of these cells, splenectomized WT mice were treated with Ang II or vehicle, carotid electric injury was induced, spleen-derived MNCs from WT or AT 1 Ϫ/Ϫ donor mice or saline were injected intravenously, and, subsequently, carotid artery reendothelialization was assessed. Figure 5D demonstrates that the diminished reendothelialization during Ang II treatment was not affected by intravenous WT cell treatment, whereas reendothelialization was significantly rescued by intravenous treatment with AT 1 Ϫ/Ϫ cells. As shown in Figure 5E , in another set of experiments, transfusion of WT cells pretreated in vitro with 
Role of AT 1 Receptors in BM-Derived Cells for Atherogenesis
BM derived from AT 1 Ϫ/Ϫ , WT, and apolipoprotein (Apo) E Ϫ/Ϫ mice was transplanted into lethally irradiated ApoE
ϩ/ϩ ApoE Ϫ/Ϫ BM in the recipient mice, respectively. Four weeks after BM transplantation (BMT), these mice were fed a high-fat, high-cholesterol diet for 7 weeks. There was no significant difference between the groups after treatment with respect to cholesterol levels in the aortic wall (AT 1 Ϫ/Ϫ BMT, 6.0Ϯ0.3 g/mg; WT BMT, 5.9Ϯ0.7 g/mg; ApoE Ϫ/Ϫ BMT, 7.2Ϯ0.4 g/mg). Figure 6A and 6B shows that atherosclerotic lesion formation in the aortic root was significantly lower in ApoE Ϫ/Ϫ mice that received AT 1 Ϫ/Ϫ BM than in those that received ApoE Ϫ/Ϫ or WT BM, indicating the relevance of AT 1 receptor expression on BM-derived cells for atherogenesis. Vascular oxidative stress, as determined by aortic reactive oxygen species production, tended to be lower in ApoE Ϫ/Ϫ mice that received AT 1 Ϫ/Ϫ BM than in mice that received ApoE Ϫ/Ϫ or WT BM (relative L-012 chemiluminescence per milligram of aortic tissue: ApoE Ϫ/Ϫ BMT, 100Ϯ28%; AT 1 Ϫ/Ϫ BMT, 65Ϯ12%, P value not significant versus ApoE Ϫ/Ϫ BMT; WT BMT, 117Ϯ20%, P value not significant versus ApoE Ϫ/Ϫ BMT). greenϭlectin, blueϭDil-acLDL, redϭcleaved caspase 3. DAPI nuclear staining is shown in the separate images. F through I, Western blot analyses were performed with total proteins of early outgrowth EPCs after cell cultivation in the presence of 1 mol/L of Ang II or vehicle (Con) for 7 days to detect phosphorylated and total forms of apoptosis signal-regulating kinase-1 (ASK-1), c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38), and total forms of Bcl-2, Bax, and ␤-actin. Representative immunoblots. 
Effect of AT 1 Receptor Antagonism on Circulating CD34/KDR-Positive EPCs in Patients With Coronary Artery Disease
To evaluate the relevance of AT 1 receptor activation for circulating EPC numbers in humans, 36 patients with stable coronary artery disease were treated with placebo, the angiotensin-converting enzyme inhibitor ramipril, or the AT 1 receptor antagonist telmisartan for 3 months in a randomized, double-blinded clinical study. Baseline characteristics did not differ between treatment groups (Table S1 ). Only telmisartan but not ramipril or placebo treatment led to a significantly increased number of circulating CD34/KDR-positive cells (primary study end point) in the peripheral blood (CD34/ KDR-positive cells per 100 000 gated events: placebo pretreatment, 5.1Ϯ1.5; placebo posttreatment, 4.4Ϯ0.8, P value not significant; ramipril pretreatment, 6.8Ϯ1.9; ramipril posttreatment, 7.5Ϯ1.4, P value not significant; telmisartan pretreatment, 6.2Ϯ1.1; telmisartan posttreatment, 18.1Ϯ4.9, PϽ0.05 versus pretreatment; Figure S4 ).
Discussion
There is ample evidence that AT 1 receptor activation by Ang II is involved in endothelial damage and atherogenesis via multiple mechanisms. 10 -12,15-18,24 We reasoned that some of the harmful consequences of Ang II could be mediated by impairment of EPCs. There is only limited knowledge about the interactions of AT 1 receptor stimulation and number and function of EPCs. Studies in humans and animals using angiotensinconverting enzyme inhibitors or AT 1 receptor blockers, which involved different pathological conditions and models, revealed conflicting results. [25] [26] [27] [28] [29] [30] Importantly, there are only few data available concerning underlying mechanisms. Again, contrasting results were shown in experimental investigations using different models. [31] [32] [33] [34] [35] [36] [37] A thorough analysis of the effects of Ang II on multiple aspects of EPC regulation and function and especially involved molecular mechanisms has not been undertaken. In this study, we demonstrate that Ang II consistently decreases the number of cultured early outgrowth EPCs in vitro and in vivo through activation of the AT 1 but not Ang II type 2 receptor and induction of apoptosis. The rate of proliferation is very low in early outgrowth EPCs and is not modulated by Ang II. In addition, Ang II impairs colonyforming and migratory capacities of early outgrowth EPCs. Importantly, reendothelialization after endothelial injury, which in part depends on functional EPCs, is decreased, and neointima formation, a process related not only to increased smooth muscle cell proliferation but also to decreased Our data indicate that Ang II induces increased reactive oxygen species production in early outgrowth EPCs and that this induction of oxidative stress accounts for the Ang II-mediated reduction of early outgrowth EPC numbers, because this effect can be blocked by cotreatment with an antioxidant. This finding is in agreement with other studies, indicating the importance of oxidative stress in EPCs during diabetes mellitus-associated impairment of reendothelialization capacities and Ang II-mediated acceleration of senescence of EPCs. 24, 31, 34 However, the molecular mechanisms involved in Ang II-induced effects in EPCs are incompletely understood. Our data demonstrate for the first time that Ang II, through the AT 1 receptor, activates the proapoptotic ASK-1 signaling pathway in early outgrowth EPCs. Ang II enhances phosphorylation of ASK-1, c-Jun N-terminal kinase, and p38-mitogen-activated protein kinase, decreases expression of antiapoptotic Bcl-2, and increases expression of proapoptotic Bax, leading to activation of caspase 3 and apoptosis ( Figure 7) . ASK-1 is a member of the mitogen- activated protein kinase kinase kinase family, which activates both c-Jun N-terminal kinase and p38-mitogen-activated protein kinase pathways. 38 p38-mitogen-activated protein kinase inhibition in vitro and in vivo improves number and functional capacities of BM-derived MNCs and EPCs, which is associated with reduced atherosclerosis in atherosclerotic mice. 39, 40 ASK-1 constitutes a pivotal signaling pathway in stress-induced apoptosis, especially in the context of oxidative stress, and was demonstrated to be activated by the pro-oxidant NADPH oxidase, an enzyme known to be stimulated by Ang II. 41, 42 Consistently, our data show that Ang II-induced activation of ASK-1 and caspase 3, resulting in apoptosis, is mediated through induction of oxidative stress, because both effects are inhibited by coincubation with an antioxidant.
Although the influence of progenitor cells on experimental atherosclerosis is not clear at present, 14, 16, 43, 44 EPCs might reduce atherosclerotic lesion formation via continuous restoration of intact endothelium but are impaired by AT 1 receptor activation. Disruption of AT 1 a receptors in the BM by BMT, leading to inhibition of Ang II/AT 1 receptor influence on EPCs residing in this compartment, significantly reduced atherosclerosis development in cholesterol-fed ApoE Ϫ/Ϫ mice and resulted in a trend toward reduced vascular oxidative stress. These data support the above concept. However, it has to be acknowledged that this experimental approach is nonselective, and direct experimental evidence is lacking. No specific EPC-directed intervention was available because of the lack of EPC-specific marker proteins. Ang II affects the entire MNC pool, and other cell lineages, such as hematopoietic cells, are also deprived of AT 1 receptors after BMT, and, thus, in addition to the beneficial effect on EPCs, other infiltrating cells, such as monocytes/macrophages, may have a less atherogenic phenotype after AT 1 receptor disruption, contributing to decreased atherosclerosis development. Our finding is in agreement with other studies showing reductions of atherosclerosis after transplantation of AT 1 a receptordeficient BM in ApoE Ϫ/Ϫ or low-density lipoprotein receptor-knockout mice. 45, 46 These studies used the model of Ang II-driven atherosclerosis with high doses of Ang II, which differs from the model of cholesterol-induced atherosclerosis, as used in our study.
Treatment of patients with stable coronary artery disease with the AT 1 receptor blocker telmisartan for 3 months significantly increased the number of circulating CD34/KDRpositive cells, which supports the hypothesis that AT 1 receptor activation by Ang II decreases EPC numbers in humans and especially in the setting of atherosclerotic disease. Our findings are in agreement with an AT 1 receptor blocker study in diabetics but in contrast with studies in patients with hypertension and acute coronary syndromes. 25, 30, 47 Treatment durations differed, and our study enrolled patients with stable coronary artery disease, which resembles a different pathological setting. Treatment with the angiotensin-converting enzyme inhibitor ramipril had no significant effect on the number of circulating CD34/KDR-positive cells, which is in contrast with previous studies. 47, 48 It can only be speculated why the angiotensin-converting enzyme inhibitor did not exert a comparable effect in our study. First, the number of enrolled patients was limited. Second, the time course of action may be different between the drugs. Third, it was demonstrated that telmisartan increases EPC numbers in vitro through a peroxisome proliferator-activated receptor-␥-dependent mechanism independent of blocking Ang II. 49 Given 
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this additional mechanism, telmisartan might have a selectively pronounced effect on EPCs compared with ramipril within a given treatment period. Our clinical trial was designed as a translational study to obtain mechanistic insight and to confirm our cell culture and animal data in humans. While corroborating our preclinical findings regarding EPC counts, the study is clearly limited by the small sample size and short duration of treatment. Therefore, effects on EPCs cannot be linked with clinical outcome, and conclusions about clinical impact on atherosclerosis and cardiovascular events are not possible.
Perspectives
Pharmacological blockade of the renin-angiotensin system, leading to diminished actions of Ang II, was demonstrated to be vasculoprotective in experimental studies and clinical trials. Our findings show that Ang II, through activation of the AT 1 receptor, oxidative stress, and involvement of redoxsensitive ASK-1-dependent proapoptotic pathways, impairs number and function of EPCs in vitro and in vivo, resulting in diminished vascular regeneration ( Figure 7 ). This demonstrates an important pathological effect of the renin-angiotensin system that contributes to impaired endothelial regeneration and possibly atherogenesis and may potentially represent a vasculoprotective treatment target, especially in future cell-based therapies. 
Methods
Materials
Angiotensin II, PD123319, PEG-SOD, tiron, DCF, oil red O solution, Evans blue, salts, and other chemicals were purchased from Sigma. L-012 was purchased from Wako Chemicals. Irbesartan was obtained from Sanofi-Aventis.
Preparation of mononuclear cells
Mononuclear cells (MNCs) were isolated from 20 ml sodium citrate-buffered peripheral blood from healthy subjects or buffy-coat preparations derived from healthy blood donors (both: age 20-35 years, male and female, no known disease or medication) using a Ficoll density gradient (Biocoll Separating Solution; Biochrom) according to standard protocols, as previously described 1 . For mouse MNCs, spleens were explanted, mechanically minced, and MNCs were isolated using a Ficoll gradient (Lympholite-M, Cedarlane).
Early outgrowth endothelial progenitor cells
Human or mouse MNCs (1x10 6 ) were seeded on fibronectin-coated (Sigma) 24-well plates in endothelial basal medium (EBM) with supplements (Promocell), as previously described 1 . After 7 days of culture, cells were washed and incubated with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (Dil)-labeled acetylated low-density lipoprotein (acLDL; CellSystems) and stained with FITC-labeled Ulex europaeus agglutinin (lectin; Sigma) for human early outgrowth endothelial progenitor cells (EPCs), and FITC-labeled Giffonia (bandeiraea) simpliciforia lectin I (Vector Laboratories) for mouse EPCs, respectively. Cells double-positive for acLDL and lectin staining were considered to be early outgrowth EPCs Immunocytochemistry was performed to further characterize these human early outgrowth EPCs. After 7 days of culture, fibronectin-adherent cells were stained with acLDL and lectin, washed and incubated with BSA (3%), primary antibodies against VEGF receptor-2, CD31, CD34, P-eNOS (Abcam), AT1 receptor or AT2 receptor (Santa Cruz), respectively, and a CY5-coupled secondary antibody (Invitrogen). Nuclei were stained with DAPI (Sigma). Fluorescence was visualized with a DM2000 microscope with DAPI (358 nm), FITC (488 nm), CY3 (555 nm) and CY5 (647nm) filters, respectively (Leica Microsystems). MNCs were cultured in supplemented endothelial basal medium in the presence of vehicle, angiotensin II and different inhibitors, respectively, for the indicated time points. Culture medium and substances were exchanged every other day, unless indicated differently.
Cell proliferation
Cell proliferation was assessed by BrdU incorporation and quantified by BrdU FACS analysis, as previously described 3 . Briefly, MNCs were cultured as described above. BrdU (20 µmol/l; Beckton Dickinson) was added during the final 48h. Cells were fixed and stained with an anti-BrdU monoclonal antibody (Beckton Dickinson) and 3 subsequently with propidium iodide in the presence of DNase-free RNase A (Roche). Measurements of the immunofluorescent cells were performed using a FACS Calibur analyzer and analyzed with CellQuestPro software (Becton Dickinson). Cell doublets were discriminated from G2 cells based on the difference in pulse shape. At least 20,000 cells were analyzed per sample. As an additional approach, Ki67 immunocytochemistry was performed. MNCs were cultured for 7 days as described above. Fibronectin-adherent cells were stained with acLDL and lectin, washed and incubated with BSA (3%), Ki67 primary antibody (Abcam) and a CY5-coupled secondary antibody (Invitrogen). Nuclei were stained with DAPI. Fluorescence was visualized with a DM2000 microscope with DAPI (358 nm), FITC (488 nm), CY3 (555 nm) and CY5 (647nm) filters, respectively (Leica Microsystems). As a positive control, subconfluent cultured human umbilical vein endothelial cells were used.
Apoptosis
To determine early outgrowth EPC apoptosis, the Cell Death Detection ELISA Kit (Roche) was used according to the instructions of the manufacturer, as previously described 1 . Briefly, after cell culture, cells were pelleted, lysed, and transferred to a streptavidin-coated microplate well. Anti-histone (biotin-labelled) and anti-DNA (peroxidase-conjugated) antibodies were added leading to the binding of nucleosome complexes to streptavidin. Samples were incubated with peroxidase substrate (ABTS) and the coloured product was measured spectrophotometrically. As an additional approach, cleaved (active) caspase-3 immunocytochemistry was performed. MNCs were cultured for 7 days as described above. Fibronectin-adherent cells were stained with acLDL and lectin, washed and incubated with BSA (3%), cleaved caspase-3 primary antibody (Abcam) and a CY5-coupled secondary antibody (Invitrogen). Nuclei were stained with DAPI. Fluorescence was visualized with a DM2000 microscope with DAPI (358 nm), FITC (488 nm), CY3 (555 nm) and CY5 (647nm) filters, respectively (Leica Microsystems).
Endothelial cell-colony forming units
For endothelial cell-colony forming units (EC-CFU), also called CFU-Hill, 5x10 6 human MNCs were isolated and sub-cultured on fibronectin-coated plates for 48h, as described above. 1x10 6 cells derived from the supernatant were re-seeded per well and cultured for additional 7 days in EBM with supplements on human fibronectin pre-coated wells with change of medium every second day, as previously described 1 . The number of colonies per well was manually counted. The number of mouse EC-CFU was determined accordingly using 5x10 6 spleen-derived MNCs.
Migration
Early outgrowth EPC migratory function was evaluated using a modified Boyden chamber (Becton Dickinson). A polycarbonate filter with 8-µm pore size (Becton Dickinson) was placed between the upper and lower chambers. After 4 days of initial culture, cell suspensions (1x10 5 cells per well) were placed in the upper chamber, and the lower chamber was filled with EBM containing 50 ng/ml of human recombinant stromal cell-derived factor-1 (SDF-1; R&D Systems). Cells were then incubated for 4 additional 24h. The migrated cells on the lower side of the filter were fixed and stained for acLDL/lectin. Migration activity was evaluated by the mean number of acLDL/lectinpositive cells counted in at least 3 high-power fields per filter.
Western blotting
MNCs were cultured for 7 days as described above. Fibronectin-adherent cells were collected and total proteins (15-20 µg) were extracted, separated by SDS-PAGE, transferred to nitrocellulose membranes and incubated overnight at 4°C with primary antibodies against phosphorylated and total forms of ASK-1 (Abcam), p38 MAPK, JNK (Cell Signaling Technology), and total forms of Bcl-2 (Abcam) and Bax (Santa Cruz), respectively. After incubation with secondary antibodies, signals were revealed by chemiluminescence (Western Lightning Plus ECL, Perkin Elmer) with the Molecular Imager Chemidoc XRS system (Bio-Rad) and quantified by densitometry using Quantity One software (Bio-Rad). Membranes were subsequently stripped and re-probed with a β-actin antibody (Sigma) to verify equal loading.
Real-time reverse transcription-polymerase chain reaction
Total RNA was isolated from human MNCs and cultured early outgrowth EPCs and from bone marrow extracted from mouse femurs, reverse transcribed and amplified by realtime RT-PCR using SYBR Green dye, as previously described 4 . The following primers were used: AT1 receptor (mouse), 5'-GGG-TGG-ACA-ATG-GCC-AGG-TAG-3' (sense), 5'-CTC-GCC-CTG-GCT-GAC-TTA-TGC-3' (antisense); AT1 receptor (human), 5`-CTG-GAA-GGC-ATA-ATT-ACA-TAT-TTG-TCA-3´ (sense), 5´-GCC-ACA-GTC-TTC-ACG-TTC-ATA-TAA-AA-3´ (antisense); AT2 receptor (human), 5´-TCC-CCT-TGT-TTG-GTG-TAT-GGC-C-3´ (sense), 5´-CAC-TGC-GGA-GCT-TCT-GTT-GGA-A-3´ (antisense); 18s rRNA, 5'-TTG-ATT-AAG-TCC-CTG-CCC-TTT-GT-3' (sense), 5'-CGA-TCC-GAG-GGC-CTC-ACT-A-3' (antisense); GAPDH, 5´-CCT-GGA-CCA-CCC-AGC-CCA-GCA-3´ (sense), 5´-TGT-TAT-GGG-GTC-TGG-GAT-GGA-3´ (antisense). For quantification, mRNA expression of the target gene was normalized to the expressed housekeeping gene 18S rRNA or GAPDH.
Flow cytometry
Flow cytometry to enumerate EPC numbers in mice and humans was performed as recently described by our group 1, 2, 5 . Mouse blood was analyzed as previously described. The viable lymphocyte population was analyzed for sca-1-FITC (Becton Dickinson) and flk-1-PE (Becton Dickinson). Isotype-identical antibodies served as controls in every experiment (Becton Dickinson). Ficoll-concentrated MNCs were used for analysis of human EPCs. Blood samples were processed with the fluorescent-conjugated antibodies CD34-FITC (Becton-Dickinson) and KDR-PE (Miltenyi). For identification of KDR-positive cells, indirect immunolabeling was performed using a biotinylated goat mononuclear antibody against the extracellular domain of human KDR (R&D Systems). IgG 2 a -FITC and IgG 2 a -PE (Pharmingen) served as negative controls. Cell fluorescence was measured immediately after staining using a FACS Calibur instrument (Becton Dickinson). Data were analyzed using CellQuestPro software (Becton Dickinson). Units of all measured components are absolute cell counts obtained after measuring of 50,000 events Table S1 . Baseline characteristics of patients with angiographically documented coronary artery disease receiving placebo, ramipril or telmisartan treatment.
Values are expressed as mean±SEM, where appropriate. LDL, low-density lipoprotein;
ASA, acetylsalicylic acid; NS, non significant. 
